I t has been firmly established that cardiac resynchronization therapy (CRT) reduces symptoms and decreases morbidity and mortality [1] [2] [3] [4] [5] [6] in a subgroup of patients who remain in moderate to severe chronic heart failure (HF) (New York Heart Association [NYHA] class III/IV) despite optimal medication. These patients are characterized by wide QRS on the surface ECG as a sign of ventricular dyssynchrony and poor left ventricular (LV) systolic function with ejection fraction (LVEF) of Յ35%. This is now a Class I recommendation, Level of Evidence A indication for CRT in US and European guidelines for practice. [7] [8] [9] [10] The recent focus in CRT studies has been to investigate whether CRT can prevent or reverse disease progression in patients with mild HF symptoms. This review aims at assessing the current evidence of a beneficial effect of CRT in earlier stages of HF.
Classification of HF
The classification of severity of HF has varied in recent years. Mild, moderate, and severe are levels of symptomatic HF. "Mild" describes minimal functional limitations, dyspnea, or fatigue; "severe" is reserved for patients who are markedly symptomatic and need frequent medical attention; and "moderate" includes all patients in between mild and severe. Because of the poor correlation between symptoms and severity of cardiac dysfunction, the 2005 American College of Cardiology/American Heart Association (ACC/AHA) guidelines introduced a new 4-stage classification to better discriminate the degrees of HF, its substrate, and its prognosis. 11 Stage A includes patients at risk of developing HF who have no structural or functional abnormality (Figure 1 ). Stage B indicates the presence of structural heart disease strongly associated with the development of HF, particularly LV systolic dysfunction, although without present or past manifestations of HF. Stage C corresponds to past or present symptomatic HF associated with structural heart disease. The clinical outcomes of patients in NYHA functional class I/stage B are presumably different from those of patients in class I/stage C, although this difference has not been confirmed. Stage D, which corresponds to NYHA functional class IV, indicates the presence of advanced HF and prominent symptoms at rest despite optimal medical treatment. The ACC/AHA classification thus highlights the growing importance of preventing disease progression as part of HF management, a critically important treatment goal both in the early stage and in stage C, to prevent the progression of HF in asymptomatic or mildly symptomatic patients.
Evolving Goals of Treatment in HF
Because of better survival after myocardial infarction, improved diagnostic methods, and the aging of the population, chronic HF caused by LV systolic dysfunction has increasing prevalence. In the United States, there are Ϸ5 million HF patients in a total population of Ϸ294 million, 12 and in Europe, there are Ϸ10 million HF patients in a total of Ϸ666 million people. These data, however, do not include patients with asymptomatic LV systolic dysfunction, which is estimated to have at least the same prevalence. 13, 14 In a large review, Wang et al 14 concluded that half of all patients with impaired systolic function were asymptomatic. Drug treatment, particular drugs that modify neurohormonal activation, reduces HF morbidity and mortality, which is otherwise poor if the underlying cause cannot be treated. 15, 16 Overt HF symptoms generally follow asymptomatic LV systolic dysfunction and are linked to increased morbidity and mortality. 14, 15, 17 In the Studies of Left Ventricular Dysfunction (SOLVD) prevention study, the development of HF was studied in patients with asymptomatic LV systolic dysfunction defined by an LVEF Ͻ35%. Thirty percent in the placebo group compared with 21% in the enalapril group developed overt HF over 8.3 years. 16 In the Framingham study, a mortality rate of 40% in asymptomatic patients with a marginally reduced LVEF (Ͻ50%) was found over 5 years. 17 If bundle-branch block accompanies LV systolic dysfunction, the overall prognosis becomes worse. 18 Healthcare expenditure on HF typically accounts for 1% to 2% of total health budgets. Costs for hospitalizations constitute 60% to 70% of these costs. 19, 20 Any intervention on top of optimal HF medication that could slow or even reverse disease progression and thereby reduce hospitalizations may help to reduce healthcare expenditures in these patients. It is possible that CRT may prove to be such an additive treatment.
End Points for Assessing Disease Progression in Clinical Trials of Patients in NYHA Class I/II and Their Relation to Earlier and Recent CRT Studies
In the early studies of CRT focusing on patients in severe HF, the primary or secondary end points were measures of symptoms such as 6-minute walk distance, 21 quality-of-life score, 22 and peak oxygen consumption, 23 all severely impaired in NYHA class III/IV HF patients (the Table) . These end points were consistently improved by CRT compared with control therapy. However, in NYHA class II patients or patients in NYHA class I with previous HF symptoms, end points based on symptomatic improvements may not be relevant or may take long periods of observation over many years to change. Indeed, the Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) II study 25 focusing solely on patients in NYHA class II, the primary end point, peak oxygen uptake, did not change significantly after 6 months of CRT compared with the control treatment. Moreover, there were no significant differences between CRT patients and control subjects relative to 6-minute walk dis-tance, quality-of-life score, or NYHA class. Instead, a marked placebo effect previously described in device studies 31 was observed in both treatment assignments. These observations agree with those in the subgroup of patients in NYHA class I/II in the CONTAK CD study. 24 The explanation could be 3-fold. Either mildly symptomatic patients in NYHA class II cannot be expected to experience symptomatic improvement, or the observation time for such improvements needs to be longer than 6 to 12 months, perhaps many years. Third, the quality-of-life instrument or other measures of symptoms used might not be sensitive enough to detect a difference in mildly symptomatic patients. 22 Packer 32 suggested a composite end point to assess HF patients in clinical trials more globally that classifies patients as being improved, unchanged, or worsened based on the combination of death, hospitalizations for HF, crossover to the opposite randomization arm as a result of worsening of HF, NYHA class, and the patient's own global assessment of health. Despite a lack of significant symptomatic improvements in the MIRACLE ICD II trial, the distribution of this end point was statistically significant at 6 months in favor of CRT. 25 Therefore, this end point was also selected as the primary end point in recent studies like Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) described below. 
Value and Limitations of Reverse Remodeling
Early trials of new treatments are generally not powered for morbidity or mortality. Reverse remodeling is still considered a surrogate end point but is linked to morbidity and mortality, which is why it was chosen as a powered secondary end point in the REVERSE study. Although patients with pathological LV remodeling undergo progressive worsening of HF, slowing or reversing of remodeling has only recently been recognized as a goal of treatment. 33 Reverse remodeling by angiotensin-converting enzyme inhibitors and in particular ␤-blockers 34 has been linked to reduced morbidity and mortality in all classes of systolic HF. Reverse remodeling is also a consistent finding in the CRT trials. 35, 36 
Results of Randomized Studies on CRT in NYHA Class I/II HF Patients Early Studies: CONTAK CD and MIRACLE ICD II
CONTAK CD enrolled NYHA class II patients along with those in NYHA class III and IV with a planned subgroup analysis of the NYHA class II patients. 24 Although the study was limited by the instability of the NYHA classes and medical therapy at enrollment and by a major change in the study protocol midway, no significant symptomatic improvement in the CRT compared with the control group was achieved in patients in NYHA class II at baseline. Nonetheless, CRT was linked to significant improvement in LV dimensions but not LVEF over either 3 or 6 months in NYHA class II patients.
In the MIRACLE ICD II, a total of 186 patients with NYHA class II HF and a classic indication for an implantable cardioverter-defibrillator (ICD) were randomized to receive CRT (CRT-ON group) or no CRT (CRT-OFF group) for 6 months. 25 This relatively small randomized, double-blind, parallel-controlled study included NYHA class II HF patients on optimal medical therapy in sinus rhythm, with QRS Ն130 ms, LVEF Յ35%, and LV end-diastolic diameter Ն55 mm (the Table) . One hundred one patients were randomized to CRT-OFF and 85 to CRT-ON. The median age of the patients was 63 years; the mean QRS duration was 165 and 166 ms; and the underlying cause of HF was ischemic heart disease in 57%. Ninety-five percent were on angiotensin-converting enzyme inhibitors, but relatively few (63%) were on ␤-blockers. Despite HF medication, the LV function was as poor as in the previous CRT trials on NYHA class III/IV HF patients The study did not meet its primary end point, which was peak oxygen uptake. Nor did classic end points used in the previous CRT studies in NYHA class III/IV patients [1] [2] [3] [4] [5] [6] change between randomization groups. In contrast, the clinical composite response 32 comparing the distribution of improved, unchanged, or worsened status showed a statistically significant improvement in favor of CRT with a value of Pϭ0.01. Additionally, significant and substantial LV reverse remodeling was found in patients with ischemic and nonischemic HF origins with a marked effect twice as high in ischemic compared with nonischemic patients. 30 These improvements were accompanied by a significant delay in time to first HF hospitalization, indicating that reverse remodeling was not an isolated finding but was linked to reduced morbidity. These findings were the reason for the REVERSE, 27, 28 the Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy (MADIT-CRT), 29 and the Resynchronization/Defibrillation for Ambulatory Heart Failure Trial (RAFT) 30 trials that all aimed at assessing whether CRT improves the clinical condition and prevents disease progression in such HF patients.
REVERSE, 12 Months and 24 Months
The purpose of the REVERSE 27,28 study was to assess the safety and efficacy of CRT in addition to optimal medical therapy in patients with asymptomatic or mild (ACC/AHA stage C, NYHA class I or II) HF in a large parallel randomized trial with a double-blind duration of 12 months in the United States and 24 months in Europe. Because only mildly symptomatic or asymptomatic patients were included, the primary end point was the percent worsened by HF clinical composite response, and not the traditional analysis of this end point (ie, the distribution of worsened, unchanged, or improved status). 32 The prospectively powered secondary end point was LV end-systolic volume index. Among other secondary end points were hospitalizations for worsening of HF and mortality.
Six hundred ten patients with NYHA class I or II HF with a QRS Ն120 ms and an LVEF Յ40% received a CRT device (with or without an ICD) and were randomly assigned at a 2:1 ratio to active CRT (CRT-ON; nϭ419) or control (CRT-OFF; nϭ191). 27 Baseline characteristics indicated that patients were younger, had narrower QRS and better quality-of-life scores, and walked further on the 6-minute walk test than patients in previous trials of both NYHA class III/IV patients 1,4,5 and NYHA class II patients. 25 Despite better compliance with medication according to HF guidelines than in previous CRT studies, impairment of LV function in patients in REVERSE was comparable to the patients in these studies.
At 12 months in the main study, there were no significant differences in the primary end point. Sixteen percent of patients in CRT-ON worsened in the clinical composite HF end point compared with 21% in CRT-OFF (Pϭ0.10). The change in the 6-minute walk distance at 12 months, quality of life by the Minnesota score and the Kansas City score, and NYHA classification did not improve with CRT. Importantly, patients assigned to CRT-ON experienced a much greater improvement in LV end-systolic volume index and other measures of LV remodeling. As previously observed, 35 the extent of reverse remodeling was 2 to 3 times greater in nonischemic heart disease compared with ischemic heart disease. Time to first HF hospitalization was significantly delayed in CRT-ON (hazard ratio [HR], 0.47; Pϭ0.03; Figure 2A) .
The results of the European patients who remained in their double-blind assignment for 24 months were recently reported. 28 In this long-term follow-up of 262 European patients, 180 were assigned to CRT-ON and 82 to CRT-OFF. Unlike in the main study, 27 19% patients worsened in the CRT-ON group compared with 34% in the CRT-OFF group (Pϭ0.01). However, no significant difference in 6-minute walk distance, quality of life, or NYHA classification was observed between groups. LV end-systolic volume index decreased by a mean of 27.5Ϯ31.8 mL/m 2 in the CRT-ON group compared with 2.7Ϯ25.8 mL/m 2 in the CRT-OFF group (PϽ0.0001). Reverse remodeling by CRT was thus progressive, with the greatest effect during the first 6 months and further improvements developing over the following 12 months. This progressive reverse remodeling was accompanied by a significant delay in time to first HF hospitalization or death (HR, 0.38; Pϭ0.003) with CRT ( Figure 2B ), suggesting that CRT prevents the progression of disease in patients with asymptomatic or mildly symptomatic LV dysfunction when supplied over 1 to 2 years.
MADIT-CRT Trial
The primary objective of MADIT-CRT was to determine whether CRT plus ICD therapy (CRT-D) in high-risk, relatively asymptomatic patients with ischemic and nonischemic cardiomyopathy would significantly reduce the combined end point of all-cause mortality or HF events, whichever appeared first, compared with ICD therapy alone. 29 The secondary objectives were measures of reverse remodeling after 12 months with all-cause mortality as one of the tertiary end points. To be included, patients with ischemic origin had to be in NYHA class I or II, and those with nonischemic origin had to be in NYHA class II. All had to have LVEF Ͻ30% and sinus rhythm with QRS Ͼ130 ms (the Table) . Randomization was stratified by origin and center. Length of follow-up for the individual patient depended on date of study entry because all patients were followed up to a common study termination date. The assumption was that CRT-D would result in a 25% reduction in the 2-year cumulative end point compared with ICD alone. A total of 1820 patients were randomized to CRT-D (nϭ1089) or ICD (nϭ731) in a 3:2 fashion. Fifty-five percent had ischemic causes of HF, and 15% were in NYHA class I at the time of enrollment. Almost all patients were on angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers (97%) and ␤-blockers (93%).
The primary end point occurred in 187 of 1089 patients in the CRT-D group (17.2%) and 185 of 731 patients in the ICD-only group (25.3%) (HR, 0.66; Pϭ0.001) with a mean follow-up of 2.4 years. The benefit was driven by a 41% reduction in the risk for HF events with an equal effect in patients with ischemic or nonischemic origins. Analyzing the Kaplan-Meier estimate of HF survival probability shows that there was an early diverging of curves in favor of CRT-D already after 2 months (Figure 3 ). The annual mortality rate (3%) was equally low in both randomization arms. Moreover, significant reverse LV remodeling was found at 1 year with a mean increase in LVEF of 11%, a drop in mean LV end-diastolic volume of 52 mL, and a drop in LV end-systolic volume of 57 mL. RAFT 30 will enroll 1800 patients in NYHA class II HF and study whether the addition of CRT to optimal medical therapy and ICD is effective in patients with LVEF Յ30% and LV end-diastolic diameter Ն60 mm (the Table) . Unlike REVERSE and MADIT-CRT, the RAFT study includes patients in atrial fibrillation. The primary end point is a composite of total mortality and HF hospitalizations.
The Ongoing RAFT Trial

Special Issues The QRS Duration Revisited
In both the REVERSE and MADIT-CRT studies, subgroup analysis showed a strong correlation between baseline QRS duration and the clinical benefit of CRT. In MADIT-CRT, 29 CRT-D was associated with a greater clinical benefit in patients with a QRS Ն150 ms (HR, 0.48; 95% confidence interval, 0.37 to 0.64) than in those with QRS Ͻ150 ms (HR, 1.06; 95% confidence interval, 0.74 to 1.52; Pϭ0.001 for interaction). The same was observed in REVERSE at 24 months 27 ; CRT-ON was associated with a lower worsening rate in the clinical composite response in patients with QRS Ն152 ms (HR, 0.23; 95% confidence interval, 0.10 to 0.56) than in those with QRS Ͻ152 ms (HR, 0.80; 95% confidence interval, 0.35 to 1.85).
These data contrast with previous randomized clinical trials in more severe HF in which no correlation was observed between baseline QRS and the clinical response to CRT. Is the predictive value of baseline QRS restricted to NYHA class I/II patients? Probably not. It can be assumed that previous trials in NYHA class III/IV failed to demonstrate such a correlation because of the very low proportion of patients with baseline QRS Ͻ150 ms ranging from 0% 1 to 12%. 2 In REVERSE and MADIT-CRT, the proportion of patients with QRS Ͻ150 ms was 35% and 40%, increasing the chance to demonstrate a significant interaction.
Selection of CRT With a Biventricular ICD Versus CRT With a Biventricular Pacemaker
CRT can be delivered by means of a biventricular ICD (CRT-D) or a biventricular pacemaker (CRT-P). In NYHA class III/IV patients, CRT reduces mortality 5 and the risk of sudden death. 26 Adding an ICD to CRT is expected to amplify the effect on mortality by reducing the risk of arrhythmic death (estimated 55% reduction in Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure [COMPANION] 4 ). However, the survival benefit of CRT-D over CRT-P is still a matter of debate. A posthoc direct comparison of CRT-D versus CRT-P in COMPANION 34 showed no difference (Pϭ0.33) in all-cause mortality. No data are available in NYHA class I/II because all patients in MADIT-CRT 29 and a large majority in REVERSE 27 received an ICD. There are, however, several arguments in favor of preferentially implanting CRT-Ds in asymptomatic or mildly symptomatic patients. NYHA class I/II patients are younger and have fewer comorbidities. Epidemiological studies report a much higher proportion of sudden versus nonsudden cardiac deaths in NYHA class I/II patients compared with NYHA class III/IV patients in whom the leading cause of death is progressive HF. 37, 38 However, this has to be balanced with a relatively low total mortality rate in NYHA class I/II patients. In REVERSE, the mortality rates observed in patients treated with optimal pharmacological regimens were 2.2% at 12 months in the overall population 27 and 5% at 24 months in the European cohort. 28 In MADIT-CRT, all patients received an ICD, but the mortality rate was equally low in both randomization arms. Finally, the possible survival benefit conferred by CRT-D in NYHA class I/II must be balanced against the risk of ICD-related complications, in particular lead failure 39 and inappropriate shocks that might lead to myocardial damage. 40
Safety Issues, Risk-to-Benefit Ratio, and Cost-Effectiveness of Therapy
Because the clinical benefits conferred by CRT are likely to be smaller and more delayed in patients presenting in NYHA class I/ II than in patients in NYHA class III/ IV, particular attention has to be paid to treatment risk and risk-to-benefitratio. In REVERSE, 9.5% suffered an LV lead-related complication, 86% of which were resolved without adverse clinical consequences. Therefore, the incremental risk of adding CRT to ICD is acceptable when the expected clinical benefit is considered.
Analyses of the COMPANION and Cardiac Resynchronization-Heart Failure (CARE-HF) trials indicate that both CRT-P and CRT-D are cost-effective in patients presenting in NYHA HF class III or IV, assuming a willingness to pay thresholds of approximately $10 000 for CRT-P and $25 000 to $35 000 for CRT-D per quality-adjusted life-year gained. 41, 42 A health economics analysis of REVERSE in the European patients is in progress.
Conclusions
Today, CRT is indicated only in moderate to severe (NYHA class III/IV) HF patients with broad QRS. The concordant results of REVERSE and MADIT-CRT indicate that CRT also might be an important additive treatment in mildly symptomatic HF patients. Therefore, a wider use of CRT in mildly symptomatic patients to prevent disease progression needs to be considered in the near future. First, however, whether mortality is influenced by CRT needs to be clarified, as well as the balance between the risks of CRT treatment and the potential benefits.
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